Oral lichen planus after certolizumab pegol treatment in a patient with Crohn's disease

Mocciaro, Filippo; Orlando, Ambrogio; Renna, Sara; Rizzuto, Maria Rosa; Cottone, Mario

doi:10.1016/j.crohns.2011.01.003

Cited by 20 publications

(12 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They suggested that TNF-alpha inhibition may precipitate lichenoid reactions through disruption of delicate balance between TNF-alpha and interferon-alpha in susceptible patients. Similar result was found with a patient with Crohn’s disease after certolizumab pegol treatment (36). Hence the issue remains controversial and more studies are called for further evidence if or not these drugs have a role in the treatment of lichen planus.…”

Section: Results and Discusionsupporting

confidence: 88%

Immunomodulatory drugs: Oral and systemic adverse effects

et al. 2014

View full text Add to dashboard Cite

Objectives: The main objectives are to present the different adverses effects of the immunomodulatory drugs that can impair the quality of life of the immunosupressed patients and study the impact of immunomodualtion on oral diseases. Immunomodulatory drugs have changed the treatment protocols of many diseases where immune functions play a central role, such as rheumatic diseases. Their effect on oral health has not been systematically investigated, however. Study Design: We review current data on the new immunomodulatory drugs from the oral health perspective based on open literature search of the topic. Results: These target specific drugs appear to have less drug interactions than earlier immunomodulating medicines but have nevertheless potential side effects such as activating latent infections. There are some data showing that the new immunomodulatory drugs may also have a role in the treatment of certain oral diseases such as lichen planus or ameliorating symptoms in Sjögren´s syndrome, but the results have not been overly promising. Conclusions: In general, data are sparse of the effect of these new drugs vs. oral diseases and there are no properly powered randomized controlled trials published on this topic. Key words:Immunomodulatory drugs, oral diseases, adverse effects, therapeutic action.

show abstract

Section: Results and Discusionsupporting

confidence: 88%

Immunomodulatory drugs: Oral and systemic adverse effects

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Of note, cases of infection or osteonecrosis of the jaw during infliximab or adalimumab therapy have been reported . Oral paradoxical reactions to biologicals include oral lichenoid reaction to infliximab and new onset of oral lichen planus during certolizumab pegol use …”

Section: Spectrum Of Oral Manifestations In Ibdmentioning

confidence: 99%

Review article: non‐malignant oral manifestations in inflammatory bowel diseases

Κατσάνος

Torres

Roda

et al. 2015

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Patients with inflammatory bowel diseases (IBD) may present with lesions in their oral cavity. Lesions may be associated with the disease itself representing an extraintestinal manifestation, with nutritional deficiencies or with complications from therapy. Aim To review and describe the spectrum of oral nonmalignant manifestations in patients with inflammatory bowel diseases [ulcerative colitis (UC), Crohn's disease (CD)] and to critically review all relevant data. Methods A literature search using the terms and variants of all nonmalignant oral manifestations of inflammatory bowel diseases (UC, CD) was performed in November 2014 within Pubmed, Embase and Scopus and restricted to human studies. Results Oral lesions in IBD can be divided into three categories: (i) lesions highly specific for IBD, (ii) lesions highly suspicious of IBD and (iii) nonspecific lesions. Oral lesions are more common in CD compared to UC, and more prevalent in children. In adult CD patients, the prevalence rate of oral lesions is higher in CD patients with proximal gastrointestinal tract and/or perianal involvement, and estimated to range between 20% and 50%. Oral lesions can also occur in UC, with aphthous ulcers being the most frequent type. Oral manifestations in paediatric UC may be present in up to one‐third of patients and are usually nonspecific. Conclusions Oral manifestations in IBD can be a diagnostic challenge. Treatment generally involves managing the underlying intestinal disease. In cases presenting with local disabling symptoms and impaired quality of life, local and systemic medical therapy must be considered and/or oral surgery may be required.

show abstract

“…There are reports on paradoxical triggering of erosive lichen planus during infliximab treatment (Worsnop et al , ) and of de novo oral lichen planus occurrence after certolizumab pegol treatment in a patient with Crohn's disease (Mocciaro et al , ) and some of carcinomas after tacrolimus use (Mattsson et al , & Güngör et al , & de Araújo et al , ).…”

Section: Mouth Precancerous Lesions In Ibdmentioning

confidence: 99%

Mouth cancer in inflammatory bowel diseases

2016

View full text Add to dashboard Cite

Mouth cancer is a major health problem. Multiple risk factors for developing mouth cancer have been studied and include history of tobacco and alcohol abuse, age over 40, exposure to ultraviolet radiation, human papilloma virus infection (HPV), nutritional deficiencies, chronic irritation, and existence or oral potentially malignant lesions such as leukoplakia and lichen planus. An important risk factor for mouth cancer is chronic immunosuppression and has been extensively reported after solid organ transplantation as well as HIV-infected patients. Diagnosis of inflammatory bowel disease (IBD) is not yet considered as a risk factor for oral cancer development. However, a significant number of patients with IBD are receiving immunosuppressants and biological therapies which could represent potential oral oncogenic factors either by direct oncogenic effect or by continuous immunosuppression favoring carcinogenesis, especially in patients with HPV(+) IBD. Education on modifiable risk behaviors in patients with IBD is the cornerstone of prevention of mouth cancer. Oral screening should be performed for all patients with IBD, especially those who are about to start an immunosuppressant or a biologic.

show abstract

Oral lichen planus after certolizumab pegol treatment in a patient with Crohn's disease

Cited by 20 publications

References 8 publications

Immunomodulatory drugs: Oral and systemic adverse effects

Immunomodulatory drugs: Oral and systemic adverse effects

Review article: non‐malignant oral manifestations in inflammatory bowel diseases

Mouth cancer in inflammatory bowel diseases

Contact Info

Product

Resources

About